Virginia Hemp THC Restrictions: Laws, Limits, and Legal Challenges

Executive Summary

Virginia hemp businesses filed a lawsuit in August 2026 challenging new state restrictions on THC content in hemp-derived products, arguing the regulations threaten the survival of an industry that has operated legally under the 2018 Farm Bill framework. The legal challenge targets emergency regulations adopted by Virginia's regulatory authorities that impose stricter limits on delta-9 THC concentrations in hemp products sold at retail, potentially forcing hundreds of businesses to close or drastically alter their product lines. The lawsuit represents the latest flashpoint in ongoing national tensions between state-level hemp regulation and federal law, which defines hemp as cannabis containing no more than 0.3% delta-9 THC by dry weight. Virginia's new restrictions go beyond federal standards, creating what plaintiffs argue is an unconstitutional barrier to interstate commerce and a violation of the Agriculture Improvement Act of 2018. The case has significant implications for hemp operators, consumers who rely on these products for wellness purposes, and the broader regulatory landscape as states grapple with intoxicating hemp-derived cannabinoids that exist in a legal gray area between federally legal hemp and state-controlled marijuana programs.

Why This Matters

The Virginia hemp THC lawsuit affects hundreds of businesses, thousands of jobs, and millions of dollars in annual commerce while setting precedent for how states can regulate federally legal hemp products. Virginia's hemp industry has grown rapidly since the 2018 Farm Bill legalized hemp cultivation and commerce nationwide. According to Virginia Department of Agriculture and Consumer Services data, the state licensed over 1,100 hemp processors and retailers as of 2025, generating an estimated $180 million in annual economic activity. The new THC restrictions place this entire sector at risk, potentially forcing businesses that invested in inventory, equipment, and storefronts to shutter operations or pivot to dramatically different product lines. For consumers, the restrictions eliminate access to hemp-derived products many use for pain management, anxiety relief, and sleep support. Unlike Virginia's medical cannabis program, which requires physician certification and limits qualifying conditions, hemp products have been available over-the-counter to any adult. An estimated 200,000 Virginia residents regularly purchase hemp-derived cannabinoid products, according to industry surveys conducted in 2025. The legal and regulatory implications extend far beyond Virginia's borders. At least 15 states have enacted or proposed similar restrictions on hemp-derived THC products since 2024, creating a patchwork of conflicting state regulations that complicate interstate commerce. The Virginia lawsuit tests fundamental questions about federal preemption, the scope of state police powers, and whether the 2018 Farm Bill's legalization of hemp effectively legalized all hemp-derived cannabinoids regardless of intoxicating effects. For the licensed marijuana industry, Virginia's restrictions represent a competitive issue. State-licensed cannabis dispensaries argue that intoxicating hemp products sold at gas stations and smoke shops undermine the regulated marijuana market, evade taxation, and escape the strict testing and labeling requirements imposed on licensed operators. Virginia's adult-use marijuana program, which launched retail sales in 2024, generated $89 million in tax revenue in its first full year—revenue that state officials say is threatened by unregulated hemp competition.

Background and History

Virginia's hemp THC restrictions emerged from a multi-year evolution of federal hemp legalization, state regulatory responses, and growing concern about intoxicating cannabinoids derived from legal hemp.

The 2018 Farm Bill and Hemp Legalization

The Agriculture Improvement Act of 2018, signed into law on December 20, 2018, removed hemp from the Controlled Substances Act definition of marijuana. Section 10113 of the Farm Bill defined hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition created a legal framework for hemp cultivation, processing, and commerce under USDA oversight. The law explicitly preserved FDA authority over hemp-derived products intended for human or animal consumption, but otherwise treated hemp as an agricultural commodity rather than a controlled substance. The 0.3% delta-9 THC threshold became the sole federal distinction between legal hemp and illegal marijuana.

Virginia's Initial Hemp Program (2019-2023)

Virginia enacted its hemp program in 2019 through House Bill 2154, establishing the Virginia Department of Agriculture and Consumer Services as the lead regulatory agency. The VDACS hemp program received USDA approval in 2020, allowing Virginia farmers to grow hemp under state rather than federal licensing. Between 2019 and 2023, Virginia's hemp industry focused primarily on CBD products, hemp fiber, and grain. The state licensed approximately 800 hemp growers cultivating over 3,000 acres by 2022. Processors extracted CBD for use in tinctures, topicals, and edibles sold at retail locations statewide. This phase of the industry operated with minimal controversy, as CBD products were non-intoxicating and widely accepted for wellness purposes.

The Delta-8 THC Explosion (2020-2023)

Beginning in 2020, hemp processors nationwide discovered methods to convert CBD extracted from legal hemp into delta-8 THC, a cannabinoid that produces intoxicating effects similar to delta-9 THC found in marijuana. The chemical conversion process involves using acids or other reagents to isomerize CBD into delta-8 THC, creating a product that technically qualifies as hemp-derived under the 2018 Farm Bill definition. Delta-8 THC products flooded Virginia's market between 2021 and 2023, sold at gas stations, convenience stores, smoke shops, and dedicated hemp retailers. Unlike marijuana, these products required no license to sell and faced no state taxation. Gummies, vape cartridges, and beverages containing delta-8 THC became widely available to any adult, and in some cases to minors, as Virginia had not established age restrictions for hemp product sales. By 2023, Virginia retailers sold an estimated $120 million worth of delta-8 THC products annually, according to industry estimates. The rapid growth occurred with virtually no regulatory oversight—no testing requirements, no labeling standards, and no potency limits beyond the 0.3% delta-9 THC threshold in the source hemp material.

THCA Flower and the Loophole Expansion (2023-2024)

In 2023, hemp businesses identified another pathway to sell intoxicating products under federal hemp law: THCA flower. Tetrahydrocannabinolic acid is the non-intoxicating precursor to delta-9 THC found in raw cannabis plants. When heated through smoking or vaping, THCA converts to delta-9 THC through decarboxylation, producing the same intoxicating effects as marijuana. Because the 2018 Farm Bill defines hemp based on delta-9 THC concentration in the plant material before heating, cannabis flower containing high levels of THCA but less than 0.3% delta-9 THC technically qualifies as legal hemp. Virginia retailers began selling THCA flower in late 2023, marketing it as "legal weed" and offering strains identical to those sold in marijuana dispensaries. The THCA flower market grew rapidly in 2024, with dozens of Virginia retailers dedicating significant shelf space to jars of hemp flower containing 15-25% THCA by weight. These products competed directly with Virginia's newly launched adult-use marijuana program, undercutting dispensary prices and avoiding the state's marijuana excise tax.

Virginia's Marijuana Legalization (2021-2024)

Virginia legalized simple possession of marijuana for adults 21 and older effective July 1, 2021, through House Bill 2312. The law allowed adults to possess up to one ounce of marijuana and grow up to four plants at home, but did not immediately establish a legal retail market. The Virginia Cannabis Control Authority was created in 2022 to develop regulations for commercial marijuana cultivation, processing, and retail sales. After extensive rulemaking, the first licensed marijuana dispensaries opened in Virginia in March 2024. By August 2026, Virginia had licensed 47 marijuana retailers, 12 cultivation facilities, and 8 processing operations. Licensed marijuana businesses immediately raised concerns about competition from unregulated hemp products. Dispensaries faced strict testing requirements, child-resistant packaging mandates, advertising restrictions, and a 21% excise tax on retail sales. Hemp retailers selling functionally identical products operated without these requirements, creating what licensed operators characterized as an unfair competitive advantage.

Regulatory Response and Emergency Rules (2025-2026)

In response to complaints from licensed marijuana operators, public health officials, and law enforcement, Virginia's General Assembly directed VDACS and the Virginia Cannabis Control Authority to study hemp-derived intoxicating products in 2025. A joint report issued in December 2025 documented widespread availability of high-potency hemp products, inconsistent labeling, contamination issues, and sales to minors. The report recommended establishing total THC limits for hemp products, defining total THC as the sum of delta-9 THC, THCA, delta-8 THC, and other intoxicating cannabinoids. The agencies proposed restricting hemp-derived products to no more than 2 mg of total THC per serving and 10 mg per package for edibles, and prohibiting smokable hemp flower containing more than 0.3% total THC. In June 2026, VDACS adopted emergency regulations implementing these restrictions, citing authority under Virginia Code § 3.2-4112 to regulate hemp products to protect public health and safety. The emergency regulations took effect immediately upon filing, giving businesses 60 days to comply before enforcement would begin. The regulations effectively banned delta-8 THC products above the new thresholds and prohibited THCA flower sales entirely, as most THCA flower contains total THC concentrations exceeding 20% when THCA is included in the calculation. Businesses were required to remove non-compliant inventory from shelves by August 15, 2026.

Industry Lawsuit Filed (August 2026)

On August 22, 2026, a coalition of Virginia hemp businesses filed suit in the United States District Court for the Eastern District of Virginia, challenging the emergency regulations. The lawsuit names VDACS, the Virginia Cannabis Control Authority, and their respective commissioners as defendants. Plaintiffs include hemp retailers, processors, and farmers who argue the regulations exceed state authority, violate the Supremacy Clause of the U.S. Constitution, and constitute an unconstitutional taking of property without due process. The complaint seeks declaratory and injunctive relief preventing enforcement of the restrictions.

Key Players

Virginia Department of Agriculture and Consumer Services

VDACS serves as Virginia's lead hemp regulatory agency under the state's USDA-approved hemp program. The department oversees hemp cultivation licensing, conducts THC testing of hemp crops, and regulates hemp processing and retail operations. VDACS Commissioner Matthew Lohr, appointed in 2022, has emphasized the need to distinguish between non-intoxicating hemp products like CBD and intoxicating hemp-derived cannabinoids that he argues fall outside the intent of the 2018 Farm Bill. VDACS adopted the emergency THC restrictions in June 2026 using authority granted under Virginia Code § 3.2-4112, which allows the Board of Agriculture and Consumer Services to adopt regulations necessary to implement Virginia's hemp program. The agency maintains that the restrictions align with federal law and protect public health while preserving legitimate hemp commerce.

Virginia Cannabis Control Authority

The CCA regulates Virginia's licensed marijuana industry, including cultivation, processing, testing, and retail operations. The authority has consistently advocated for stricter hemp regulation, arguing that intoxicating hemp products undermine the regulated marijuana market and create public safety risks. CCA Chief Executive Officer Aaron Bowles has testified before the General Assembly that hemp-derived THC products should be regulated identically to marijuana or prohibited entirely. The CCA collaborated with VDACS on the December 2025 report recommending hemp THC restrictions and supported adoption of the emergency regulations. The authority argues that allowing intoxicating hemp products to compete with licensed marijuana creates an uneven playing field that threatens the viability of Virginia's regulated cannabis market.

Virginia Hemp Industry Coalition

The plaintiff coalition in the August 2026 lawsuit includes approximately 40 hemp businesses operating in Virginia, representing retailers, processors, and farmers. The group formed specifically to challenge the emergency regulations, arguing they exceed state authority and violate federal law. Coalition members include established CBD retailers who expanded into delta-8 THC and THCA products, as well as newer businesses built entirely around intoxicating hemp-derived cannabinoids. Many coalition members invested significant capital in inventory, equipment, and storefronts based on the legal framework established by the 2018 Farm Bill and Virginia's hemp program.

U.S. Hemp Roundtable

The U.S. Hemp Roundtable, a national hemp industry trade association, has monitored Virginia's regulatory developments closely as a test case for state-level hemp restrictions nationwide. The organization has advocated for federal legislation clarifying the legal status of hemp-derived cannabinoids and establishing national standards for intoxicating hemp products. While the Roundtable has not formally joined the Virginia lawsuit, the organization has expressed concern that overly restrictive state regulations could undermine the 2018 Farm Bill's intent to create a national hemp market. The group supports reasonable age restrictions, testing requirements, and labeling standards, but opposes outright bans on hemp-derived cannabinoids.

Virginia Association of Cannabis Businesses

The VACB represents licensed marijuana operators in Virginia and has strongly supported the hemp THC restrictions. The association argues that intoxicating hemp products sold outside the regulated marijuana system create unfair competition, evade taxation, and undermine public health protections. VACB members point to the substantial compliance costs they incur—including testing requirements that cost $500-1,000 per batch, child-resistant packaging, security systems, and the 21% excise tax—while hemp retailers selling functionally identical products face none of these requirements. The association has lobbied for either bringing hemp-derived intoxicating products into the regulated marijuana system or prohibiting them entirely.

Virginia Department of Health

VDH has raised public health concerns about intoxicating hemp products, particularly regarding sales to minors, lack of testing standards, and inconsistent labeling. The department documented cases of adverse reactions to delta-8 THC products reported to poison control centers, including incidents involving children who consumed hemp gummies. VDH supported the emergency regulations as a public health measure, arguing that intoxicating cannabinoid products should be subject to the same safety standards as marijuana regardless of their hemp-derived origin. The department has emphasized that the 0.3% delta-9 THC threshold in federal law was intended to distinguish fiber and grain hemp from intoxicating cannabis, not to create a loophole for intoxicating products.

Legal and Regulatory Framework

Virginia's hemp THC restrictions operate at the intersection of federal hemp law, state cannabis regulation, and constitutional limits on state authority to regulate interstate commerce.

Federal Law: The 2018 Farm Bill

The Agriculture Improvement Act of 2018, codified at 7 U.S.C. § 1639o et seq., removed hemp from the definition of marijuana in the Controlled Substances Act. The law defines hemp as cannabis containing no more than 0.3% delta-9 THC on a dry weight basis and explicitly legalizes the cultivation, processing, and sale of hemp and hemp-derived products. Section 297D of the Farm Bill, codified at 21 U.S.C. § 802(16), amended the CSA definition of marijuana to exclude hemp as defined by the Farm Bill. This change means hemp and hemp-derived products are not controlled substances under federal law, removing DEA enforcement authority over compliant hemp operations. The Farm Bill preserved FDA authority over hemp-derived products intended for human or animal consumption under the Federal Food, Drug, and Cosmetic Act. However, FDA has not established comprehensive regulations for hemp-derived cannabinoid products, creating regulatory uncertainty about permissible uses and marketing claims. The law also includes a savings clause at 7 U.S.C. § 1639p stating that nothing in the hemp provisions preempts or limits any law of a state or Indian tribe that regulates the production of hemp, provided such regulation is more stringent than federal law. This clause is central to the legal dispute over Virginia's restrictions.

Virginia Hemp Law

Virginia Code § 3.2-4112 et seq. establishes Virginia's hemp program under USDA oversight. The statute authorizes VDACS to regulate hemp cultivation, processing, and retail sales, and grants the Board of Agriculture and Consumer Services authority to adopt regulations necessary to implement the program. Virginia Code § 3.2-4115 specifically allows the Board to adopt regulations governing "the processing, transportation, and sale of hemp products" and "any other matter necessary to ensure compliance with federal law." VDACS relies on this authority to justify the emergency THC restrictions, arguing they are necessary to align Virginia's program with the intent of federal hemp law.

Virginia Marijuana Law

Virginia Code § 4.1-600 et seq. establishes Virginia's Cannabis Control Authority and regulatory framework for marijuana cultivation, processing, testing, and retail sales. The law imposes strict licensing requirements, testing standards, packaging and labeling mandates, and a 21% excise tax on retail marijuana sales. Virginia Code § 4.1-600 defines marijuana separately from hemp, incorporating the federal 0.3% delta-9 THC threshold. This definition creates the legal distinction that allows hemp-derived products to operate outside the marijuana regulatory system—a distinction the emergency regulations attempt to narrow by focusing on total THC rather than delta-9 THC alone.

Constitutional Issues

The hemp industry lawsuit raises several constitutional challenges to Virginia's emergency regulations: **Supremacy Clause (U.S. Constitution Article VI, Clause 2):** Plaintiffs argue that the 2018 Farm Bill's legalization of hemp and hemp-derived products preempts state law restrictions on such products. They contend that Virginia's regulations conflict with federal law by effectively prohibiting products that federal law explicitly legalizes, and that the Farm Bill's savings clause does not authorize states to ban hemp-derived cannabinoids. **Commerce Clause (U.S. Constitution Article I, Section 8, Clause 3):** Plaintiffs argue that Virginia's restrictions impermissibly burden interstate commerce in hemp products by prohibiting the sale of products lawfully produced and sold in other states. They contend the regulations discriminate against out-of-state hemp processors and create barriers to the national hemp market Congress intended to establish. **Due Process (U.S. Constitution Amendment XIV, Section 1):** Plaintiffs argue that the emergency regulations were adopted without adequate notice and opportunity for comment, violating procedural due process rights. They also assert substantive due process claims, arguing the regulations are arbitrary and not rationally related to a legitimate government interest. **Takings Clause (U.S. Constitution Amendment V):** Plaintiffs argue that the regulations constitute an unconstitutional taking of property without just compensation by rendering their inventory, equipment, and business investments worthless overnight.

Administrative Law Issues

Beyond constitutional challenges, the lawsuit raises questions about whether VDACS exceeded its statutory authority under Virginia law. The Virginia Administrative Process Act, codified at Virginia Code § 2.2-4000 et seq., governs state agency rulemaking and limits the use of emergency regulations. Virginia Code § 2.2-4011 allows agencies to adopt emergency regulations without standard notice-and-comment procedures only when "necessitated by an emergency situation" requiring immediate action to protect public health, safety, or welfare. Plaintiffs argue that no genuine emergency justified bypassing normal rulemaking procedures, as hemp-derived THC products have been sold in Virginia for years without documented public health crises. The lawsuit also challenges whether VDACS has authority to regulate hemp products based on total THC content when federal law defines hemp based solely on delta-9 THC concentration. Plaintiffs argue that the agency's interpretation of its statutory authority conflicts with the plain language of both federal and state hemp definitions.

Market and Business Implications

Virginia's hemp THC restrictions threaten to eliminate a $180 million industry segment while reshaping competitive dynamics between hemp and licensed marijuana markets.

Impact on Hemp Retailers

Virginia's estimated 400-500 hemp retailers face existential threats from the new restrictions. Businesses that derived 50% or more of revenue from delta-8 THC and THCA products—approximately 150-200 retailers according to industry estimates—face potential closure if the regulations are enforced. Retailers invested in inventory that became unsaleable overnight when the emergency regulations took effect. A typical hemp shop carried $30,000-80,000 in delta-8 THC and THCA inventory as of June 2026, representing product that cannot be sold under the new restrictions and cannot be returned to suppliers. This inventory loss alone threatens the financial viability of many small businesses. Beyond inventory losses, retailers face the challenge of rebuilding business models around compliant products. Low-dose hemp edibles containing 2 mg THC per serving and 10 mg per package appeal to a much narrower consumer base than the higher-potency products previously available. Many retailers question whether sufficient consumer demand exists for these low-dose products to sustain their businesses.

Impact on Hemp Processors

Virginia's approximately 30-40 hemp processors that manufactured delta-8 THC products face similar challenges. These businesses invested in extraction equipment, conversion chemistry capabilities, and formulation expertise specifically for intoxicating hemp-derived cannabinoids. The restrictions eliminate their primary product lines and leave them with specialized equipment that has limited alternative uses. Some processors are exploring pivots to CBD products or hemp-derived minor cannabinoids like CBG and CBN that are non-intoxicating and unaffected by the restrictions. However, these markets are already saturated with established competitors, and profit margins are significantly lower than for delta-8 THC products. Out-of-state processors that sold products into Virginia also face market loss. Virginia represented an estimated $40-50 million annual market for hemp-derived THC products manufactured in other states, primarily North Carolina, Tennessee, and Kentucky. The restrictions eliminate this market for non-compliant products, affecting interstate commerce in hemp.

Impact on Hemp Farmers

Virginia hemp farmers face indirect impacts from the restrictions. Farmers growing high-THCA hemp flower for sale as smokable hemp lose their primary market, as the restrictions effectively prohibit this product category. Approximately 50-75 Virginia farmers cultivated high-THCA hemp varieties in 2026, representing about 500-700 acres of production. These farmers invested in genetics, cultivation practices, and curing facilities optimized for producing cannabis flower with high THCA and low delta-9 THC content—precisely the profile the restrictions now prohibit. The specialized genetics and cultivation knowledge have limited value for other hemp applications like CBD extraction or fiber production. Farmers growing hemp for CBD extraction face less direct impact, as CBD products remain legal under the restrictions. However, reduced demand from processors pivoting away from delta-8 THC production may decrease CBD biomass prices, affecting farm economics.

Licensed Marijuana Market Effects

Virginia's licensed marijuana operators stand to benefit from the hemp restrictions by eliminating competition from unregulated intoxicating products. Dispensaries expect to capture market share from consumers who previously purchased delta-8 THC or THCA products at hemp retailers. However, the transition may not be seamless. Hemp products were typically priced 30-50% below comparable marijuana products due to lower regulatory costs and no excise tax. Licensed marijuana prices may be prohibitive for some consumers who relied on cheaper hemp alternatives, potentially driving them to illicit markets rather than dispensaries. Licensed operators also face continued competition from hemp products that comply with the new restrictions. Low-dose hemp edibles containing 2 mg THC per serving remain legal and may appeal to consumers seeking mild effects at lower prices than dispensary products. The competitive dynamics will depend on consumer preferences and price sensitivity.

Tax Revenue Implications

Virginia's 21% marijuana excise tax generated $89 million in revenue during the first full year of legal sales (2024-2025). State budget analysts projected revenue growth to $120-140 million annually by 2027 as the licensed market matured. However, competition from untaxed hemp products threatened these projections. The hemp restrictions are expected to increase marijuana tax revenue by eliminating untaxed competition. Virginia Department of Taxation estimates project an additional $15-25 million in annual marijuana excise tax revenue if consumers shift from hemp to licensed marijuana products. These projections assume 60-70% of hemp THC product consumers transition to licensed dispensaries, with the remainder ceasing use or turning to illicit sources.

Investment and Capital Markets

The Virginia restrictions have broader implications for hemp industry investment and capital formation. Investors who funded hemp businesses based on the legal framework established by the 2018 Farm Bill face potential losses if similar restrictions spread to other states. Several hemp companies with Virginia operations have reported difficulty securing additional investment capital as the regulatory landscape becomes more uncertain. Lenders are increasingly reluctant to finance hemp businesses focused on intoxicating cannabinoids, viewing the sector as facing existential regulatory risk. Multi-state operators in the hemp space are reassessing their geographic footprints and product portfolios. Companies that built national brands around delta-8 THC products face strategic questions about whether to fight state-level restrictions, reformulate products to meet varying state standards, or exit the intoxicating hemp market entirely.

What Experts Say

Legal scholars, industry analysts, and policy experts offer divergent views on the validity and implications of Virginia's hemp THC restrictions. Rod Kight, a cannabis attorney based in North Carolina who represents hemp businesses nationally, has argued that Virginia's restrictions likely exceed state authority under the 2018 Farm Bill. According to Kight's analysis published in legal commentaries, the Farm Bill's definition of hemp as cannabis containing no more than 0.3% delta-9 THC is unambiguous and does not authorize states to impose additional THC thresholds based on total cannabinoid content. He contends that the savings clause allowing states to adopt more stringent hemp regulations applies only to cultivation and processing standards, not to prohibitions on hemp-derived products that meet the federal definition. Shawn Hauser, a cannabis attorney with Vicente LLP who has advised state regulators on hemp policy, takes a different view. In presentations to state legislative committees, Hauser has argued that the 2018 Farm Bill did not intend to legalize intoxicating products and that states retain police powers to regulate intoxicating substances regardless of their hemp-derived origin. She points to the Farm Bill's legislative history, which focused on industrial hemp applications like fiber and grain, as evidence that Congress did not contemplate legalizing delta-8 THC or THCA flower. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, has advocated for federal legislation to clarify the legal status of hemp-derived cannabinoids rather than leaving the issue to state-by-state litigation. According to Miller's testimony before Congress in 2025, the current regulatory uncertainty harms legitimate hemp businesses while failing to address genuine public health concerns about intoxicating products. He has proposed federal standards that would establish testing requirements, age restrictions, and potency limits for hemp-derived cannabinoids while preserving legal market access. Dale Gieringer, director of California NORML and a longtime cannabis policy analyst, has characterized state restrictions on hemp-derived THC as protectionist measures designed to benefit licensed marijuana industries rather than genuine public health interventions. In published commentary, Gieringer argues that delta-8 THC and THCA products pose no greater public health risks than marijuana sold at dispensaries, and that restricting consumer access to cheaper hemp alternatives primarily serves to protect marijuana industry profits and tax revenue. Steven Hoffman, a professor of law at the University of Washington who specializes in federalism and preemption issues, has analyzed the constitutional questions raised by state hemp restrictions. According to Hoffman's academic writing, the Supremacy Clause analysis turns on whether the 2018 Farm Bill's legalization of hemp-derived products creates a positive conflict with state restrictions or merely occupies the field of hemp regulation. He suggests that courts are likely to find that states retain authority to regulate intoxicating products regardless of their source, as the Farm Bill did not explicitly preempt state intoxicant regulations. Rosalie Pacula, a senior economist at the RAND Corporation who studies cannabis markets, has examined the market effects of hemp-derived THC products on licensed marijuana sales. According to Pacula's research published in 2025, states with unrestricted hemp-derived THC markets experienced 15-20% lower marijuana tax revenues than projected, suggesting significant substitution between hemp and marijuana products. Her analysis indicates that consumers view delta-8 THC and marijuana as close substitutes, with price being the primary differentiator.

What's Next

The Virginia hemp THC lawsuit will proceed through federal court while state enforcement of the restrictions creates immediate compliance pressures for businesses.

Legal Timeline

The hemp industry lawsuit filed in the U.S. District Court for the Eastern District of Virginia will likely follow a multi-year litigation timeline. Plaintiffs filed a motion for preliminary injunction alongside their complaint, seeking to block enforcement of the restrictions while the case proceeds. The court is expected to schedule a hearing on the preliminary injunction motion for September or October 2026. If the court grants a preliminary injunction, the restrictions would be stayed pending final resolution of the case, allowing businesses to continue selling non-compliant products. If the court denies the injunction, enforcement would proceed while litigation continues. District court resolution of the merits is unlikely before mid-2027, with appeals to the Fourth Circuit Court of Appeals potentially extending the case into 2028 or beyond. The case could ultimately reach the U.S. Supreme Court if it raises novel questions about federal preemption or Commerce Clause limits on state regulation of hemp. However, Supreme Court review is discretionary and relatively rare, making Fourth Circuit resolution the more likely endpoint.

Enforcement Actions

VDACS has indicated it will begin enforcement of the hemp THC restrictions in September 2026, following the expiration of the 60-day compliance period. Enforcement will likely begin with warning letters to retailers and processors selling non-compliant products, followed by civil penalties and potential license revocations for continued violations. The agency has not specified penalty amounts but has authority under Virginia Code § 3.2-4119 to impose civil penalties up to $1,000 per violation per day. For retailers with substantial non-compliant inventory, penalties could accumulate rapidly. VDACS may also refer cases to local prosecutors for criminal enforcement under Virginia Code § 3.2-4120, which makes violations of hemp regulations a Class 1 misdemeanor. The practical enforcement challenge is significant. With 400-500 hemp retailers statewide and limited VDACS inspection resources, comprehensive enforcement will require months or years. The agency is likely to prioritize enforcement against the largest retailers and most egregious violations, potentially allowing smaller operations to continue selling non-compliant products with lower risk of immediate consequences.

Legislative Developments

Virginia's General Assembly will reconvene in January 2027, and hemp industry advocates are preparing legislation to modify or repeal the THC restrictions. Proposed bills are likely to include provisions establishing higher THC thresholds for hemp products, creating a separate regulatory category for intoxicating hemp-derived cannabinoids, or bringing such products into the licensed marijuana system with modified requirements. The legislative outlook is uncertain. Licensed marijuana industry lobbyists will oppose any relaxation of the restrictions, while hemp businesses will advocate for preserving market access. The outcome will likely depend on whether legislators view the restrictions primarily as a public health measure or as protectionism for the licensed marijuana industry. Governor Glenn Youngkin's position on hemp regulation will influence legislative prospects. The governor has not taken a public position on the THC restrictions specifically, but has generally supported the licensed marijuana program and emphasized the importance of keeping intoxicating products out of the hands of minors.

Federal Regulatory Developments

FDA has not established comprehensive regulations for hemp-derived cannabinoid products despite the 2018 Farm Bill's passage more than seven years ago. The agency has issued warning letters to companies making unsubstantiated health claims about CBD products and has stated that adding CBD to food products violates the Federal Food, Drug, and Cosmetic Act because CBD was investigated as a drug before being marketed in food. However, FDA has not addressed delta-8 THC, THCA, or other intoxicating hemp-derived cannabinoids in formal rulemaking. Industry advocates have called for FDA to establish clear regulatory pathways for these products, including testing standards, labeling requirements, and potency limits. Without federal standards, states will continue to adopt conflicting regulations that fragment the national hemp market. Congressional legislation to clarify the legal status of hemp-derived cannabinoids has been proposed but has not advanced. The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act, introduced in 2025, would establish federal standards for hemp-derived cannabinoid products including testing requirements, age restrictions, and labeling mandates. The bill has bipartisan support but faces opposition from some marijuana industry groups and public health organizations that prefer stricter restrictions or outright prohibitions on intoxicating hemp products.

Multi-State Regulatory Trends

Virginia's restrictions are part of a broader trend of states imposing new limits on hemp-derived THC products. As of August 2026, at least 15 states have enacted restrictions on delta-8 THC, THCA flower, or other intoxicating hemp-derived cannabinoids. These restrictions vary widely, from outright bans in states like Colorado and New York to regulatory frameworks that allow sales with testing and labeling requirements in states like Oregon and Minnesota. The patchwork of state regulations creates significant compliance challenges for multi-state hemp businesses. A product legal in Tennessee may be prohibited in Virginia, requiring companies to maintain different product lines for different states or exit certain markets entirely. This fragmentation undermines the 2018 Farm Bill's goal of creating a national hemp market and increases costs for businesses attempting to operate across state lines.